drug
pemetrexed
Marketedupdated 3mo agoby Eagle Pharmaceuticals Inc
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 5indications
investigational
NSCLC
all catalysts(0)
nothing on the calendar yet
Trials studying pemetrexed
- phase3A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
- phase1A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
- phase3A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.
- phase3Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC)
- phase2GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors
- phase3A Study of BL-B01D1 in Combination With Osimertinib as Perioperative Therapy in Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer(PANKU-Lung09)
- phase2A Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLC
- phase1A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001)
Patent cliff
source: FDA Orange Bookfirst barrier falls
Mar 26, 2035
~8.6 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (6)
- Feb 19, 2036formulationUS 11793813
- Feb 19, 2036method-of-use (U-4248)US 12115164
- Oct 28, 2035compositionUS 9604990
- Mar 26, 2035formulationUS 11147817
- Mar 26, 2035formulationUS 11147817
- Mar 26, 2035formulationUS 11147817
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 1h ago
Found something off?
comments(0)
5-min edit window · permanent after that